(19)
(11) EP 3 659 664 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.01.2025 Bulletin 2025/01

(45) Mention of the grant of the patent:
27.11.2024 Bulletin 2024/48

(21) Application number: 20152392.5

(22) Date of filing: 21.10.2008
(51) International Patent Classification (IPC): 
A61M 25/098(2006.01)
A61B 17/32(2006.01)
A61M 25/00(2006.01)
 A61B 17/22(2006.01)
A61B 17/00(2006.01)
A61M 25/01(2006.01)
(52) Cooperative Patent Classification (CPC):
A61B 17/22; A61B 17/32002; A61B 2017/00469; A61B 2017/22094; A61B 2017/22095; A61M 25/0045; A61M 25/0068; A61M 25/0069; A61M 2025/0197

(54)

DEVICES FOR CROSSING CHRONIC TOTAL OCCLUSIONS

VORRICHTUNGEN ZUR ÜBERQUERUNG VON CHRONISCHEN TOTALVERSCHLÜSSEN

DISPOSITIFS POUR TRAVERSER DES OCCLUSIONS TOTALES CHRONIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 22.10.2007 US 999879 P

(43) Date of publication of application:
03.06.2020 Bulletin 2020/23

(60) Divisional application:
24215002.7

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08841515.3 / 2211968

(73) Proprietor: Boston Scientific Scimed, Inc.
Maple Grove, MN 55311 (US)

(72) Inventors:
  • JACOBS, Peter Alan
    Minneapolis, MN 55415 (US)
  • KUGLER, Chad John
    Andover, MN 55304 (US)
  • OLSON, Matthew Jonathan
    Crystal, MN 55422 (US)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)


(56) References cited: : 
JP-A- H0 473 069
US-A1- 2007 088 230
US-A1- 2007 219 464
 US-A1- 2007 083 220
US-A1- 2007 093 781
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).